Rune Sundset, Hege Sagstuen Haugnes, Alexander Perez, Ola Engelsen, Ida H H Fosseide, Miguel J Castillejo, Trond Velde Bogsrud
{"title":"¹⁷⁷Lu-PSMA放射性配体疗法治疗转移性阉割耐药前列腺癌。","authors":"Rune Sundset, Hege Sagstuen Haugnes, Alexander Perez, Ola Engelsen, Ida H H Fosseide, Miguel J Castillejo, Trond Velde Bogsrud","doi":"10.4045/tidsskr.23.0478","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Treatment of castration-resistant metastatic prostate cancer with [¹⁷⁷Lu]PSMA radioligand.</p><p><strong>Case presentation: </strong>A man in his seventies with metastatic prostate cancer received castration therapy for four years, developing castration-resistant disease. PET/CT with [⁶⁸Ga]PSMA-11 showed high uptake in metastatic lymph nodes. The patient received 7.4 GBq [¹⁷⁷Lu]PSMA-I&T (Curium, Finland) as five treatments at five-week intervals. Five weeks after the first treatment, p-PSA dropped from 154 to 53 µg/L. Five weeks after the fifth treatment, p-PSA was 1.8 µg/L. [⁶⁸Ga]PSMA-11 PET/CT showed significant reduction in the size of metastases, with the largest decreasing in diameter from 10 to 4 mm. Seven months after the fifth treatment, p-PSA increased to 14.3 µg/L, and [⁶⁸Ga]PSMA-11 PET/ CT revealed additional skeletal metastases, while the lymph node metastases remained unchanged. Thus, the treatment had a good but temporary effect on the metastases.</p><p><strong>Interpretation: </strong>Treatment with [¹⁷⁷Lu]PSMA radioligand resulted in a temporary regression of the metastases.</p>","PeriodicalId":23123,"journal":{"name":"Tidsskrift for Den Norske Laegeforening","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"¹⁷⁷Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.\",\"authors\":\"Rune Sundset, Hege Sagstuen Haugnes, Alexander Perez, Ola Engelsen, Ida H H Fosseide, Miguel J Castillejo, Trond Velde Bogsrud\",\"doi\":\"10.4045/tidsskr.23.0478\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Treatment of castration-resistant metastatic prostate cancer with [¹⁷⁷Lu]PSMA radioligand.</p><p><strong>Case presentation: </strong>A man in his seventies with metastatic prostate cancer received castration therapy for four years, developing castration-resistant disease. PET/CT with [⁶⁸Ga]PSMA-11 showed high uptake in metastatic lymph nodes. The patient received 7.4 GBq [¹⁷⁷Lu]PSMA-I&T (Curium, Finland) as five treatments at five-week intervals. Five weeks after the first treatment, p-PSA dropped from 154 to 53 µg/L. Five weeks after the fifth treatment, p-PSA was 1.8 µg/L. [⁶⁸Ga]PSMA-11 PET/CT showed significant reduction in the size of metastases, with the largest decreasing in diameter from 10 to 4 mm. Seven months after the fifth treatment, p-PSA increased to 14.3 µg/L, and [⁶⁸Ga]PSMA-11 PET/ CT revealed additional skeletal metastases, while the lymph node metastases remained unchanged. Thus, the treatment had a good but temporary effect on the metastases.</p><p><strong>Interpretation: </strong>Treatment with [¹⁷⁷Lu]PSMA radioligand resulted in a temporary regression of the metastases.</p>\",\"PeriodicalId\":23123,\"journal\":{\"name\":\"Tidsskrift for Den Norske Laegeforening\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2024-07-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Tidsskrift for Den Norske Laegeforening\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4045/tidsskr.23.0478\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/20 0:00:00\",\"PubModel\":\"Print\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tidsskrift for Den Norske Laegeforening","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4045/tidsskr.23.0478","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/20 0:00:00","PubModel":"Print","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
¹⁷⁷Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.
Background: Treatment of castration-resistant metastatic prostate cancer with [¹⁷⁷Lu]PSMA radioligand.
Case presentation: A man in his seventies with metastatic prostate cancer received castration therapy for four years, developing castration-resistant disease. PET/CT with [⁶⁸Ga]PSMA-11 showed high uptake in metastatic lymph nodes. The patient received 7.4 GBq [¹⁷⁷Lu]PSMA-I&T (Curium, Finland) as five treatments at five-week intervals. Five weeks after the first treatment, p-PSA dropped from 154 to 53 µg/L. Five weeks after the fifth treatment, p-PSA was 1.8 µg/L. [⁶⁸Ga]PSMA-11 PET/CT showed significant reduction in the size of metastases, with the largest decreasing in diameter from 10 to 4 mm. Seven months after the fifth treatment, p-PSA increased to 14.3 µg/L, and [⁶⁸Ga]PSMA-11 PET/ CT revealed additional skeletal metastases, while the lymph node metastases remained unchanged. Thus, the treatment had a good but temporary effect on the metastases.
Interpretation: Treatment with [¹⁷⁷Lu]PSMA radioligand resulted in a temporary regression of the metastases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
